Extraction of a Metal Ion Beam from a Planar Magnetron Sputter Ion Source

Wada, M.; Kanda, S.; Kuwata, Yusuke; Miyamoto, Naoki; Yoshioka, Kento

doi:10.1109/iit.2016.7882872

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, in the AML sub group RI was lower with CBT in com par i son to the haplo-SCT group (Supplemental Table 1). 11 The Center for International Blood and Marrow Transplant Research (CIBMTR) has also recently com pared 375 non-T-celldepleted haplo-SCT with PTCy to 333 CBT performed between 2012 and 2017 with myeloablative con di tion ing (MAC) in patients (adults and pedi at ric) with dif fer ent hema to log i cal malig nan-cies. Three-year OS and LFS were sim i lar.…”

Section: Haplo-stc Vs Cbt: Reg Is Try-based Stud Iesmentioning

confidence: 99%

In 2022, which is preferred: haploidentical or cord transplant?

Nagler

Mohty

2022

Hematology

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation is the treatment of choice for high-risk hematological malignancies such as acute myeloid and lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative disorders. Alternative donor transplantation from either haploidentical (haplo-SCT) or cord blood donor (CBT) is an established therapeutic alternative for patients who need transplants but lack a human leukocyte antigen–matched donor. Although haplo-SCT (mainly non–T-cell-depleted haplo-SCT with posttransplant cyclophosphamide) is increasing while CBT is decreasing worldwide (Figure 1), recent developments in CBT, especially cord blood expansion and other strategies to improve engraftment and immune reconstitution post-CBT, make CBT still a valuable option. This article discusses the 2 options based on the currently available data, focusing on adults, and tries to give some clues to help the transplant physician choose a haploidentical vs a cord blood donor. Given the limited numbers of published or ongoing well-designed randomized controlled trials comparing haplo-SCT to CBT and the overall similar clinical results in the available, mostly registry-based, and single-center studies, with substantial heterogeneity and variability, the decision to perform haplo-SCT or CBT in a given patient depends not only on the patient, disease, and donor characteristics and donor availability (although most if not all patients should have in principle an alternative donor) but also on the transplant physician's discretion and, most importantly, the center's experience and preference and ongoing protocols and strategies.

show abstract

Section: Haplo-stc Vs Cbt: Reg Is Try-based Stud Iesmentioning

confidence: 99%